RhoC is a major target of microRNA-93-5P in epithelial ovarian carcinoma tumorigenesis and progression
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
RhoC is a major target of microRNA-93-5P in epithelial ovarian carcinoma tumorigenesis and progression
Authors
Keywords
MiR-93-5P, RhoC, Ovarian epithelial carcinoma, Tumorigenesis and progression
Journal
Molecular Cancer
Volume 14, Issue 1, Pages 31
Publisher
Springer Nature
Online
2015-02-03
DOI
10.1186/s12943-015-0304-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- miRNA-17 Members that TargetBmpr2Influence Signaling Mechanisms Important for Embryonic Stem Cell Differentiation In Vitro and Gastrulation in Embryos
- (2015) Shannon M. Larabee et al. STEM CELLS AND DEVELOPMENT
- The role of RhoC in ovarian epithelial carcinoma: A marker for carcinogenesis, progression, prognosis, and target therapy
- (2013) Yang Zhao et al. GYNECOLOGIC ONCOLOGY
- De-Regulated MicroRNAs in Pediatric Cancer Stem Cells Target Pathways Involved in Cell Proliferation, Cell Cycle and Development
- (2013) Patricia C. Sanchez-Diaz et al. PLoS One
- Heading off with the herd: how cancer cells might maneuver supernumerary centrosomes for directional migration
- (2012) Angela Ogden et al. CANCER AND METASTASIS REVIEWS
- MicroRNA-93 inhibits tumor growth and early relapse of human colorectal cancer by affecting genes involved in the cell cycle
- (2012) I-Ping Yang et al. CARCINOGENESIS
- MicroRNA93 Regulates Proliferation and Differentiation of Normal and Malignant Breast Stem Cells
- (2012) Suling Liu et al. PLoS Genetics
- MicroRNAs and the cell cycle
- (2011) María José Bueno et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Mechanisms of microRNA deregulation in human cancer
- (2011) Shan Deng et al. CELL CYCLE
- Shielding the messenger (RNA): microRNA-based anticancer therapies
- (2011) Elena Sotillo et al. PHARMACOLOGY & THERAPEUTICS
- Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
- (2010) Kai Kessenbrock et al. CELL
- Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting
- (2010) Chrisostomi Gialeli et al. FEBS Journal
- Identification of MicroRNA-93 as a Novel Regulator of Vascular Endothelial Growth Factor in Hyperglycemic Conditions
- (2010) Jianyin Long et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Clinical characteristics of TIMP2, MMP2, and MMP9 gene polymorphisms in colorectal cancer
- (2010) Kyung Sook Park et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- miRNAs in human cancer
- (2010) Thalia A Farazi et al. JOURNAL OF PATHOLOGY
- RhoC expression level is correlated with the clinicopathological characteristics of ovarian cancer and the expression levels of ROCK-I, VEGF, and MMP9
- (2009) Yang Zhao et al. GYNECOLOGIC ONCOLOGY
- The role of RhoC in growth and metastatic capacity of melanoma
- (2009) Barbara Boone et al. JOURNAL OF CUTANEOUS PATHOLOGY
- RhoC Expression and Head and Neck Cancer Metastasis
- (2009) M. Islam et al. MOLECULAR CANCER RESEARCH
- Causes and consequences of microRNA dysregulation in cancer
- (2009) Carlo M. Croce NATURE REVIEWS GENETICS
- Possible role of the RhoC/ROCK pathway in progression of clear cell renal cell carcinoma
- (2008) Hideyuki ABE et al. BIOMEDICAL RESEARCH-TOKYO
- Targeted Deletion Reveals Essential and Overlapping Functions of the miR-17∼92 Family of miRNA Clusters
- (2008) Andrea Ventura et al. CELL
- MicroRNA Expression Profiles in Serous Ovarian Carcinoma
- (2008) E. J. Nam et al. CLINICAL CANCER RESEARCH
- miR-17 family miRNAs are expressed during early mammalian development and regulate stem cell differentiation
- (2008) Kara M. Foshay et al. DEVELOPMENTAL BIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started